Published in Nat Rev Urol on May 29, 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer | NCT01341652
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer (2015) 2.13
Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis. Mol Ther (2013) 1.03
Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology (2014) 0.89
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget (2016) 0.82
Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82
Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer. Vaccine (2015) 0.77
Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen? Immunotherapy (2013) 0.75
Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice. Vaccine (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inflammation and cancer. Nature (2002) 53.78
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Cancer immunotherapy comes of age. Nature (2011) 12.35
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09
Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther (1990) 3.04
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther (2000) 2.34
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007) 2.21
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 2.09
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine (2009) 1.92
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res (2009) 1.72
Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66
Features of the dendritic cell lineage. Immunol Rev (2010) 1.58
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Harnessing human dendritic cell subsets for medicine. Immunol Rev (2010) 1.46
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother (2004) 1.44
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother (2011) 1.41
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol (2006) 1.36
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol (1997) 1.30
Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun (2006) 1.29
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
The economic burden of prostate cancer. BJU Int (2011) 1.23
CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother (2008) 1.22
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol (2010) 1.09
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06
Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res (2007) 1.05
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother (2006) 1.04
Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol (2009) 1.04
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines (2006) 1.01
Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol (2001) 1.00
Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2005) 1.00
Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther (1999) 1.00
Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother (2008) 0.98
Presentation of tumour antigens by dendritic cells and challenges faced. Curr Opin Immunol (2010) 0.97
Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer (2001) 0.97
Immunotherapy with dendritic cells for prostate cancer. Int J Cancer (2007) 0.97
10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther (2011) 0.96
Lifetime economic burden of prostate cancer. BMC Health Serv Res (2011) 0.96
Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) (2006) 0.94
Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine (2006) 0.93
Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology (1998) 0.93
Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther (2010) 0.92
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol (2008) 0.92
Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin (2011) 0.91
Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol (2000) 0.89
Immunotherapeutics in development for prostate cancer. Oncologist (2009) 0.88
Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol (2000) 0.87
Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther (2005) 0.87
Immunotherapy for prostate cancer. Curr Oncol Rep (2007) 0.86
The PCa Tumor Microenvironment. Cancer Microenviron (2011) 0.86
Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther (2005) 0.85
Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res (2011) 0.85
The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol (2009) 0.85
Cancer vaccines as a therapeutic modality: The long trek. Cancer Immunol Immunother (2006) 0.85
Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy (2011) 0.84
Prostate cancer: genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis (2008) 0.84
Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol (1997) 0.83
CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Hum Gene Ther (2010) 0.83
Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene (2011) 0.80
Immunotherapy in the treatment of advanced prostate cancer. Can J Urol (2011) 0.78
Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. In Vivo (2002) 0.76
Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol (2008) 2.85
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology (2004) 2.47
Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology (2003) 1.62
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther (2005) 1.53
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol (2011) 1.53
Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate (2007) 1.28
Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther (2003) 1.26
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol (2002) 1.22
Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology (2004) 1.22
Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol (2004) 1.21
Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol (2006) 1.19
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer (2011) 1.17
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology (2003) 1.15
Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate (2007) 1.14
GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci (2010) 1.12
Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model. Mol Cancer Ther (2009) 1.11
Evaluation of ureterointestinal anastomosis: Wallace vs Bricker. J Urol (2006) 1.04
The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma. Urol Oncol (2011) 1.04
Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate (2010) 1.03
Long-term complications related to the modified Indiana pouch. Urology (2002) 1.03
Active surveillance for prostate cancer in a veteran population. Can J Urol (2010) 0.99
Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res (2009) 0.99
The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis. J Biol Chem (2012) 0.98
Ejaculatory function in stage T1 nonseminomatous germ cell tumors: retroperitoneal lymph node dissection versus surveillance--a decision analysis. J Urol (2002) 0.97
Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate (2010) 0.96
The role of soy phytoestrogens in prostate cancer. Curr Opin Urol (2005) 0.94
Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J Androl (2006) 0.94
Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis (2006) 0.93
Adrenergic regulation of salt and fluid secretion in human medullary collecting duct cells. Am J Physiol Renal Physiol (2004) 0.91
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs (2009) 0.89
Urethral diverticulum as a sequela of unrepaired penile fracture. Can J Urol (2007) 0.89
Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park) (2004) 0.89
Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol (2008) 0.88
A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells. Leuk Lymphoma (2013) 0.87
Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. Lung Cancer (2012) 0.87
The role of soy phytoestrogens in prostate cancer. Urol Clin North Am (2002) 0.87
Dose effect of soy supplementation in prostate cancer: a pilot study. Oncol Rep (2006) 0.86
Targeting the androgen receptor--theory and practice. Urology (2011) 0.85
Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol Rep (2003) 0.85
Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy (2011) 0.84
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies. Urol Clin North Am (2011) 0.83
Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Prostate (2008) 0.82
Boron chemicals in diagnosis and therapeutics. Future Med Chem (2013) 0.82
Case selection and outcome of radical perineal prostatectomy in localized prostate cancer. Int Braz J Urol (2005) 0.82
Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis. Oncol Rep (2005) 0.82
Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncol Lett (2012) 0.81
The craft of urologic surgery: modern radical perineal prostatectomy. Urol Clin North Am (2004) 0.81
Adenocarcinoma of the rete testis presenting in an undescended testicle. J Urol (2003) 0.81
Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of granulocyte colony-stimulating factor--a potential neoplastic marker: a case report and review of the literature. J Med Case Rep (2014) 0.81
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond) (2012) 0.81
Selenium concentration in the prostate. Biol Trace Elem Res (2003) 0.80
Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol (2005) 0.80
Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. PLoS One (2013) 0.80
A comparison of radical perineal, radical retropubic, and robot-assisted laparoscopic prostatectomies in a single surgeon series. Prostate Cancer (2010) 0.80
Testicular self-examination and testicular cancer: a cost-utility analysis. Cancer Med (2014) 0.80
Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. Immunotherapy (2012) 0.79
Management of the contralateral testicle in patients with unilateral testicular cancer. World J Urol (2009) 0.79
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. Prostate (2015) 0.79
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 0.78
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol (2013) 0.78
Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence. Clin Nucl Med (2014) 0.78
Predictors of positive surgical margins after radical perineal prostatectomy. Can J Urol (2009) 0.77
Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol (2004) 0.77
Refining prostate biopsy strategies. J Urol (2006) 0.75
Radical prostatectomy does not improve survival compared to observation for localised prostate cancer in a prospective randomised trial. Evid Based Med (2012) 0.75
Abandoning PSA test is a deeply flawed recommendation. Mo Med (2012) 0.75
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.75
Digital fecal occult blood testing in the ambulatory urology clinic. J Am Coll Surg (2007) 0.75
Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. J Urol (2005) 0.75
Review of the bylaws changes from the Society of Urologic Oncology 2009. Urol Oncol (2009) 0.75
Modifier 22 on perioperative outcomes of robotic assisted laparoscopic prostatectomy. Can J Urol (2014) 0.75
Circumaortic renal vein tumor thrombus in renal cell carcinoma. Int J Urol (2011) 0.75
Buccal mucosal urethroplasty in patients who had multiple previous procedures. Urology (2006) 0.75
Adjuvant radiation therapy after radical prostatectomy: when is it indicated? Curr Urol Rep (2009) 0.75
The Role of High Dose Interleukin-2 in the Era of Targeted Therapy. J Urol (2017) 0.75
Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer (2003) 0.75